Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
₩ 15820
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Encell Co. Ltd. engages in the research, development, and manufacture of biopharmaceuticals. It provides customized pharmaceutical development services, from early development stage to approval stage. The company was founded in February 2018 and is headquartered in Seoul, South Korea.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.
Data is available to registered users only
Buy
Sell